{
    "ticker": "CBDBY",
    "name": "China Biologic Products Holdings, Inc.",
    "description": "China Biologic Products Holdings, Inc. is a leading biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of human plasma-derived biologics. Established in 1998, the company operates several plasma collection stations and manufacturing facilities across China, positioning itself as a key player in the healthcare sector. China Biologic focuses on producing high-quality biological products, including immunoglobulins, albumin, and clotting factors, which are essential for treating various diseases and conditions related to the immune system, bleeding disorders, and more. With a commitment to innovation and quality, China Biologic invests significantly in R&D to enhance its product offerings and improve patient outcomes. The company's mission is to provide safe and effective therapies to patients, addressing the growing medical needs in China and globally. As the demand for plasma-derived therapies continues to rise, China Biologic aims to expand its market presence and leverage its industry expertise to contribute to public health.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Beijing, China",
    "founded": "1998",
    "website": "https://www.chinabiologic.com",
    "ceo": "Chunhua Liu",
    "social_media": {
        "linkedin": "https://www.linkedin.com/company/china-biologic-products-holdings-inc/"
    },
    "investor_relations": "https://www.chinabiologic.com/investor-relations",
    "key_executives": [
        {
            "name": "Chunhua Liu",
            "position": "CEO"
        },
        {
            "name": "Shengwen Wang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Plasma-Derived Products",
            "products": [
                "Immunoglobulin",
                "Albumin",
                "Clotting Factors"
            ]
        }
    ],
    "seo": {
        "meta_title": "China Biologic Products Holdings, Inc. | Leading Biopharmaceutical Company",
        "meta_description": "Explore China Biologic Products Holdings, Inc., a leader in plasma-derived biologics. Discover our commitment to innovative healthcare solutions and patient care.",
        "keywords": [
            "China Biologic",
            "Biopharmaceuticals",
            "Plasma-Derived Products",
            "Healthcare",
            "Immunoglobulin",
            "Albumin"
        ]
    },
    "faq": [
        {
            "question": "What products does China Biologic offer?",
            "answer": "China Biologic produces plasma-derived products such as immunoglobulin, albumin, and clotting factors."
        },
        {
            "question": "Who is the CEO of China Biologic?",
            "answer": "Chunhua Liu is the CEO of China Biologic Products Holdings, Inc."
        },
        {
            "question": "Where is China Biologic headquartered?",
            "answer": "China Biologic is headquartered in Beijing, China."
        },
        {
            "question": "When was China Biologic founded?",
            "answer": "China Biologic was founded in 1998."
        }
    ],
    "competitors": [
        "SGEN",
        "BMY",
        "AMGN",
        "RHHBY"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}